NIPER Raebareli Inks MoU with Lofty Lab to Boost Pharma Research & Biotech Collaboration

The partnership seeks to strengthen academia-industry collaboration in pharmaceutical and biotechnology research.

National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, has signed a Memorandum of Understanding (MoU) and Technology Transfer Agreement with Lofty Laboratories, Hyderabad, to boost collaborative research, innovation, and technology commercialization.

The partnership includes joint participation in research and development activities in areas of mutual interest to strengthen academia-industry collaboration in pharmaceutical and biotechnology research.

Under the partnership, both organisations agreed to adopt industry-tailored technology developed at NIPER Rae Bareli for commercialisation and development.

Commenting on the new initiative, Prof. Shubhi A. Saraf, Director, NIPER-Rae Bareli, stated that the MoU and the Technology Transfer Agreement will enable both the institutes to complement each other's research programmes in various ways, including collaborative participation in the activities of the Institute's Centre of Excellence in Innovative Drug Delivery Systems (CoE-NDDS).

The Centre of Excellence focuses on innovative drug delivery systems, including approaches, formulation, and technologies aimed at improving the safe and targeted delivery of medicinal compounds to achieve desired therapeutic outcomes.

Further, Head of the Center for Excellence in New Drug Delivery Systems, Prof. Nihar Ranjan, noted that the commercialisation of the current technology will significantly reduce the cost of gel-staining agents, which are used extensively across the globe in biology-related research, especially those involving genes, cancer, and other nucleic acid-related diseases.

He added that indigenous manufacturing of such advanced gel-staining agents would contribute to strengthening India’s pharmaceutical and biotechnology ecosystem.

In an earlier development, the National Institute of Pharmaceutical Education and Research, Hajipur, entered into a strategic partnership with Boehringer Ingelheim India to strengthen translational pharmaceutical research.

The partnership is expected to improve research capabilities, expand scientific access, and create pathways for early-stage discoveries to move toward clinical development.

Stay tuned for more such updates on Digital Health News